Novo's Wegovy Pill Reaches 38,000 Prescriptions in Week 5

• The Wegovy pill generated 38,220 prescriptions in week five post-launch based on IQVIA tracking data
• This represents the oral pill version of Wegovy, expanding beyond the existing injectable formulation
• The prescription volume provides an early indicator of market adoption for Novo Nordisk's obesity treatment portfolio

Summary: Novo Nordisk's Wegovy Pill Launch Update

Key Development:

Novo Nordisk's oral Wegovy pill reached 38,220 U.S. prescriptions in its fifth week post-launch, according to IQVIA data reported on February 13, 2026.

Company Focus:

• Novo Nordisk, the Danish pharmaceutical company, continues its expansion in the weight-loss medication market with this pill formulation of Wegovy
• The prescription data comes from IQVIA, a healthcare data analytics provider

Market Context:

The weekly prescription figure provides an important metric for tracking the commercial performance of Novo Nordisk's oral weight-loss treatment. The pill version represents a significant development in the GLP-1 medication category, which has seen explosive growth in recent years. Oral formulations typically offer improved convenience compared to injectable versions, potentially expanding market reach.

Implications:

The five-week prescription trajectory will be closely monitored by investors and analysts to assess:

• Market adoption rate and commercial viability
• Competition with existing injectable Wegovy and rival products from companies like Eli Lilly
• Revenue potential in the multi-billion-dollar obesity treatment market
• Insurance coverage and patient access trends

Limited Data:

The article provides minimal additional context about growth trends, pricing, or comparative performance metrics. Investors will need to track subsequent weekly data to determine if prescription volumes are accelerating, stabilizing, or declining from this fifth-week baseline.

This launch update is significant for Novo Nordisk shareholders and the broader pharmaceutical sector, as obesity medications remain one of the fastest-growing and most valuable therapeutic categories in the pharmaceutical industry.